Login Register Cart 0
Generic placeholder image

The Natural Products Journal

Editor-in-Chief

ISSN (Print): 2210-3155
ISSN (Online): 2210-3163

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Mechanism, Pathophysiology and Herbal Management-A Review on Irritable Bowel Syndrome

Author(s): Ankita Wal*, Pranay Wal, Neha Verma, Awani Kumar Rai and Piyush Vatsha

Volume 13, Issue 3, 2023

Published on: 09 September, 2022

Article ID: e240622206390 Pages: 15

DOI: 10.2174/2210315512666220624163105

Price: $65

Abstract

Background: The global distribution of IBS is surprisingly uniform, affecting men and women of all ages. Its deep-rooted character, symptoms that fluctuate from moderate to extreme, have several detrimental effects on the sufferer's standard of living; consequently, proper treatment of these patients is necessary. The etiology of IBS is unknown. Although several explanations were also proposed, the specific etiology of irritable bowel syndrome remains unknown. Clinical trials using stabilized therapies and new active medications have shown symptom reduction over placebo.

Objective: IBS has long been linked to visceral sensitivity and gastrointestinal motor abnormalities. The pathophysiology of IBS appears to be multifaceted. However, several of the following elements are vital in forming IBS. This paper aims to provide a complete, scientific proof assessment of the prognosis, pathogenesis, and therapy choices to assist clinicians in successfully treating their patients.

Methods: The report's information was compiled by combining numerous review articles and research papers from multiple sources, including Hindawi, Elsevier, NCBI [National Centre for Biotechnology Information], and Research Gate, from 1981 to 2021, using keywords such as IBS, Brain-gut axis, postinfectious IBS, Microbiota, low-grade inflammation, and so on.

Conclusion: The acute symptom influences the selection of medical techniques and therapy (IBS with diarrhoea, IBS with constipation, or mixed IBS). Current research demonstrates both pharmaceutical and non-pharmaceutical treatment have a positive impact (in comparison to a placebo) on irritable bowel syndrome (IBS) problems, discomfort relief, and improved health status.

Keywords: IBS, visceral hypersensitivity, Brain-gut axis, postinfectious IBS, Microbiota, gastrointestinal motor abnormalities.

Graphical Abstract

[1]
Lovell, R.M.; Ford, A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol., 2012, 10(7), 712-721.e4.
[http://dx.doi.org/10.1016/j.cgh.2012.02.029] [PMID: 22426087]
[2]
Sperber, A.D.; Bangdiwala, S.I.; Drossman, D.A.; Ghoshal, U.C.; Simren, M.; Tack, J.; Whitehead, W.E.; Dumitrascu, D.L.; Fang, X.; Fukudo, S.; Kellow, J.; Okeke, E.; Quigley, E.M.M.; Schmulson, M.; Whorwell, P.; Archampong, T.; Adibi, P.; Andresen, V.; Benninga, M.A.; Bonaz, B.; Bor, S.; Fernandez, L.B.; Choi, S.C.; Corazziari, E.S.; Francisconi, C.; Hani, A.; Lazebnik, L.; Lee, Y.Y.; Mulak, A.; Rahman, M.M.; Santos, J.; Setshedi, M.; Syam, A.F.; Vanner, S.; Wong, R.K.; Lopez-Colombo, A.; Costa, V.; Dickman, R.; Kanazawa, M.; Keshteli, A.H.; Khatun, R.; Maleki, I.; Poitras, P.; Pratap, N.; Stefanyuk, O.; Thomson, S.; Zeevenhooven, J.; Palsson, O.S. Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterology, 2021, 160(1), 99-114.e3.
[http://dx.doi.org/10.1053/j.gastro.2020.04.014] [PMID: 32294476]
[3]
Longstreth, G.F.; Thompson, W.G.; Chey, W.D.; Houghton, L.A.; Mearin, F.; Spiller, R.C. Functional bowel disorders. Gastroenterology, 2006, 130(5), 1480-1491.
[http://dx.doi.org/10.1053/j.gastro.2005.11.061] [PMID: 16678561]
[4]
Lu, C.L.; Chen, C.Y.; Lang, H.C.; Luo, J.C.; Wang, S.S.; Chang, F.Y.; Lee, S.D. Current patterns of irritable bowel syndrome in Taiwan: The Rome II questionnaire on a Chinese population. Aliment. Pharmacol. Ther., 2003, 18, 1159-1169.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01711.x]
[5]
Talley, N.J. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol. Motil., 2008, 20(s1)(Suppl. 1), 121-129.
[http://dx.doi.org/10.1111/j.1365-2982.2008.01097.x] [PMID: 18402649]
[6]
Lovell, R.M.; Ford, A.C. Effect of gender on prevalence of irritable bowel syndrome in the community: Systematic review and meta-analysis. Am. J. Gastroenterol., 2012, 107(7), 991-1000.
[http://dx.doi.org/10.1038/ajg.2012.131] [PMID: 22613905]
[7]
Drossman, D.A.; Corrazziari, E.; Delvaux, M.; Spiller, R.; Talley, N.J.; Thompson, W.G. Rome III: The Functional Gastrointestinal Disorders; Degnon Associates: McLean, VA, 2006.
[8]
Drossman, D.A.; Corazziari, E.; Talley, N.J.; Thompson, W.G.; Whitehead, W.E. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus, 2nd ed; Degnon Associates: McLean, VA, 2000.
[9]
Talley, N.J.; Spiller, R. Irritable bowel syndrome: A little understood organic bowel disease? Lancet, 2002, 360(9332), 555-564.
[http://dx.doi.org/10.1016/S0140-6736(02)09712-X] [PMID: 12241674]
[10]
Kibune, N.C.; Garcia, M.C. Silva, Lorena, S.L. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev. Esp. Enferm. Dig., 2016, 108, 59-64.
[11]
Holtmann, G.J.; Ford, A.C.; Talley, N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol., 2016, 1(2), 133-146.
[12]
Ford, A.C.; Forman, D.; Bailey, A.G.; Axon, A.T.R.; Moayyedi, P. Irritable bowel syndrome: A 10-yr natural history of symptoms and factors that influence consultation behavior. Am. J. Gastroenterol., 2008, 103(5), 1229-1239.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01740.x] [PMID: 18371141]
[13]
Brierley, S.M.; Linden, D.R. Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat. Rev. Gastroenterol. Hepatol., 2014, 11(10), 611-627.
[http://dx.doi.org/10.1038/nrgastro.2014.103] [PMID: 25001973]
[14]
Julius, D. TRP channels and pain. Annu. Rev. Cell Dev. Biol., 2013, 29(1), 355-384.
[http://dx.doi.org/10.1146/annurev-cellbio-101011-155833] [PMID: 24099085]
[15]
Mulak, A.; Bonaz, B. Irritable bowel syndrome: A model of the brain-gut interactions. Med. Sci. Monit., 2004, 10(4), RA55-RA62.
[PMID: 15260348]
[16]
Konturek, S.J.; Konturek, J.W.; Pawlik, T.; Brzozowski, T. Brain-gut axis and its role in the control of food intake. J. Physiol. Pharmacol., 2004, 55(1 Pt 2), 137-154.
[PMID: 15082874]
[17]
Mayer, E.A.; Tillisch, K. The brain-gut axis in abdominal pain syndromes. Annu. Rev. Med., 2011, 62(1), 381-396.
[http://dx.doi.org/10.1146/annurev-med-012309-103958] [PMID: 21090962]
[18]
Groot, J.; Bijlsma, P.; Van Kalkeren, A.; Kiliaan, A.; Saunders, P.; Perdue, M. Stress-induced decrease of the intestinal barrier function. The role of muscarinic receptor activation. Ann. N. Y. Acad. Sci., 2000, 915(1), 237-246.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05247.x] [PMID: 11193581]
[19]
Bonaz, B.; Sabate, J.M. Brain-gut axis dysfunction. Gastroenterol. Clin. Biol., 2009, 33(Suppl. 1), S48-S58.
[http://dx.doi.org/10.1016/S0399-8320(09)71525-8] [PMID: 19303539]
[20]
Feng, B.; La, J.H.; Schwartz, E.S.; Gebhart, G.F. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 302(10), G1085-G1098.
[http://dx.doi.org/10.1152/ajpgi.00542.2011] [PMID: 22403791]
[21]
Farmer, A.D.; Aziz, Q. Visceral pain hypersensitivity in functional gastrointestinal disorders. Br. Med. Bull., 2009, 91(1), 123-136.
[http://dx.doi.org/10.1093/bmb/ldp026] [PMID: 19620136]
[22]
Camilleri, M.; Ford, A.C. Irritable bowel syndrome: Pathophysiology and current therapeutic approaches. Handb. Exp. Pharmacol., 2017, 239, 75-113.
[http://dx.doi.org/10.1007/164_2016_102] [PMID: 27995391]
[23]
Ek, W.E.; Reznichenko, A.; Ripke, S.; Niesler, B.; Zucchelli, M.; Rivera, N.V.; Schmidt, P.T.; Pedersen, N.L.; Magnusson, P.; Talley, N.J.; Holliday, E.G.; Houghton, L.; Gazouli, M.; Karamanolis, G.; Rappold, G.; Burwinkel, B.; Surowy, H.; Rafter, J.; Assadi, G.; Li, L.; Papadaki, E.; Gambaccini, D.; Marchi, S.; Colucci, R.; Blandizzi, C.; Barbaro, R.; Karling, P.; Walter, S.; Ohlsson, B.; Tornblom, H.; Bresso, F.; Andreasson, A.; Dlugosz, A.; Simren, M.; Agreus, L.; Lindberg, G.; Boeckxstaens, G.; Bellini, M.; Stanghellini, V.; Barbara, G.; Daly, M.J.; Camilleri, M.; Wouters, M.M.; D’Amato, M. Exploring the genetics of irritable bowel syndrome: A GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64(11), 1774-1782.
[http://dx.doi.org/10.1136/gutjnl-2014-307997] [PMID: 25248455]
[24]
Farnam, A.; Somi, M.H.; Sarami, F.; Farhang, S. Five personality dimensions in patients with irritable bowel syndrome. Neuropsychiatr. Dis. Treat., 2008, 4(5), 959-962.
[PMID: 19183786]
[25]
Chang, L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology, 2011, 140(3), 761-765.
[http://dx.doi.org/10.1053/j.gastro.2011.01.032] [PMID: 21256129]
[26]
Akiho, H.; Ihara, E.; Nakamura, K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J. Gastrointest. Pathophysiol., 2010, 1(3), 97-105.
[http://dx.doi.org/10.4291/wjgp.v1.i3.97] [PMID: 21607147]
[27]
De Palma, G.; Collins, S.M.; Bercik, P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes, 2014, 5(3), 419-429.
[http://dx.doi.org/10.4161/gmic.29417] [PMID: 24921926]
[28]
Marshall, J.K.; Thabane, M.; Garg, A.X.; Clark, W.F.; Salvadori, M.; Collins, S.M. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology, 2006, 131(2), 445-450.
[http://dx.doi.org/10.1053/j.gastro.2006.05.053] [PMID: 16890598]
[29]
Drossman, D.A.; Camilleri, M.; Mayer, E.A.; Whitehead, W.E. AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123(6), 2108-2131.
[http://dx.doi.org/10.1053/gast.2002.37095] [PMID: 12454866]
[30]
Saito, Y.A.; Petersen, G.M.; Locke, G.R., III; Talley, N.J. The genetics of irritable bowel syndrome. Clin. Gastroenterol. Hepatol., 2005, 3(11), 1057-1065.
[http://dx.doi.org/10.1016/S1542-3565(05)00184-9] [PMID: 16271334]
[31]
Zhang, Z-F.; Duan, Z-J.; Wang, L-X.; Yang, D.; Zhao, G.; Zhang, L. The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: A meta-analysis of 25 studies. BMC Gastroenterol., 2014, 14(1), 23.
[http://dx.doi.org/10.1186/1471-230X-14-23] [PMID: 24512255]
[32]
Lee, Y.J.; Park, K.S. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J. Gastroenterol., 2014, 20(10), 2456-2469.
[http://dx.doi.org/10.3748/wjg.v20.i10.2456] [PMID: 24627583]
[33]
Chang, L.; Adeyemo, M.; Karagiannides, I.; Videlock, E.J.; Bowe, C.; Shih, W.; Presson, A.P.; Yuan, P.Q.; Cortina, G.; Gong, H.; Singh, S.; Licudine, A.; Mayer, M.; Tache, Y.; Pothoulakis, C.; Mayer, E.A. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am. J. Gastroenterol., 2012, 107(2), 262-272.
[http://dx.doi.org/10.1038/ajg.2011.423] [PMID: 22158028]
[34]
Collins, S.M.; Bercik, P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology, 2009, 136(6), 2003-2014.
[http://dx.doi.org/10.1053/j.gastro.2009.01.075] [PMID: 19457424]
[35]
Fichna, J.; Storr, M.A. Brain-Gut interactions in IBS. Front. Pharmacol., 2012, 3, 127.
[http://dx.doi.org/10.3389/fphar.2012.00127] [PMID: 22783191]
[36]
Ohman, L.; Simrén, M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig. Liver Dis., 2007, 39(3), 201-215.
[http://dx.doi.org/10.1016/j.dld.2006.10.014] [PMID: 17267314]
[37]
Stewart, G.T. Post-dysenteric colitis. BMJ, 1950, 1(4650), 405-409.
[http://dx.doi.org/10.1136/bmj.1.4650.405] [PMID: 15410136]
[38]
Schwille-Kiuntke, J.; Enck, P.; Zendler, C.; Krieg, M.; Polster, A.V.; Klosterhalfen, S.; Autenrieth, I.B.; Zipfel, S.; Frick, J.S. Postinfectious irritable bowel syndrome: Follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol. Motil., 2011, 23(11), e479-e488.
[http://dx.doi.org/10.1111/j.1365-2982.2011.01779.x] [PMID: 21883703]
[39]
Zoetendal, E.G.; Rajilic-Stojanovic, M.; de Vos, W.M. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut, 2008, 57(11), 1605-1615.
[http://dx.doi.org/10.1136/gut.2007.133603] [PMID: 18941009]
[40]
Carroll, I.M.; Chang, Y-H.; Park, J.; Sartor, R.B.; Ringel, Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog., 2010, 2(1), 19.
[http://dx.doi.org/10.1186/1757-4749-2-19] [PMID: 21143915]
[41]
Ford, A.C.; Quigley, E.M.; Lacy, B.E.; Lembo, A.J.; Saito, Y.A.; Schiller, L.R.; Soffer, E.E.; Spiegel, B.M.; Moayyedi, P. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: Systematic review and meta-analysis. Am. J. Gastroenterol., 2014, 109(9), 1350-1365.
[http://dx.doi.org/10.1038/ajg.2014.148] [PMID: 24935275]
[42]
Camilleri, M.; Boeckxstaens, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut, 2017, 66(5), 966-974.
[http://dx.doi.org/10.1136/gutjnl-2016-313425] [PMID: 28232472]
[43]
Henningsen, P.; Zimmermann, T.; Sattel, H. Medically unexplained physical symptoms, anxiety, and depression: A meta-analytic review. Psychosom. Med., 2003, 65(4), 528-533.
[http://dx.doi.org/10.1097/01.PSY.0000075977.90337.E7] [PMID: 12883101]
[44]
Schmid, J.; Langhorst, J.; Gaß, F.; Theysohn, N.; Benson, S.; Engler, H.; Gizewski, E.R.; Forsting, M.; Elsenbruch, S. Placebo analgesia in patients with functional and organic abdominal pain: A fMRI study in IBS, UC and healthy volunteers. Gut, 2015, 64(3), 418-427.
[http://dx.doi.org/10.1136/gutjnl-2013-306648] [PMID: 24833636]
[45]
McQuay, H.J.; Tramèr, M.; Nye, B.A.; Carroll, D.; Wiffen, P.J.; Moore, R.A. A systematic review of antidepressants in neuropathic pain. Pain, 1996, 68(2-3), 217-227.
[http://dx.doi.org/10.1016/S0304-3959(96)03140-5] [PMID: 9121808]
[46]
Saarto, T.; Wiffen, P.J. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev., 2007, 4(4), CD005454.
[PMID: 17943857]
[47]
Gorard, D.A.; Libby, G.W.; Farthing, M.J. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment. Pharmacol. Ther., 1994, 8(2), 159-166.
[http://dx.doi.org/10.1111/j.1365-2036.1994.tb00273.x] [PMID: 8038347]
[48]
Ruepert, L.; Quartero, A.O.; de Wit, N.J.; van der Heijden, G.J.; Rubin, G.; Muris, J.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev., 2011, 2013(8), CD003460.
[http://dx.doi.org/10.1002/14651858.CD003460.pub3] [PMID: 21833945]
[49]
Tack, J.; Fried, M.; Houghton, L.A.; Spicak, J.; Fisher, G. Systematic review: The efficacy of treatments for irritable bowel syndrome-A European perspective. Aliment. Pharmacol. Ther., 2006, 24(2), 183-205.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02938.x] [PMID: 16842448]
[50]
Camilleri, M.; Lembo, A.; Katzka, D.A. Opioids in gastroenterology: Treating adverse effects and creating therapeutic benefits. Clin. Gastroenterol. Hepatol., 2017, 15(9), 1338-1349.
[http://dx.doi.org/10.1016/j.cgh.2017.05.014] [PMID: 28529168]
[51]
Enck, P.; Aziz, Q.; Barbara, G.; Farmer, A.D.; Fukudo, S.; Mayer, E.A.; Niesler, B.; Quigley, E.M. Rajilić-Stojanović M.; Schemann, M.; Schwille-Kiuntke, J.; Simren, M.; Zipfel, S.; Spiller, R.C. Irritable bowel syndrome. Nat. Rev. Dis. Primers, 2016, 2(1), 16014.
[http://dx.doi.org/10.1038/nrdp.2016.14] [PMID: 27159638]
[52]
Wade, P.R.; Palmer, J.M.; McKenney, S.; Kenigs, V.; Chevalier, K.; Moore, B.A.; Mabus, J.R.; Saunders, P.R.; Wallace, N.H.; Schneider, C.R.; Kimball, E.S.; Breslin, H.J.; He, W.; Hornby, P.J. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist. Br. J. Pharmacol., 2012, 167(5), 1111-1125.
[http://dx.doi.org/10.1111/j.1476-5381.2012.02068.x] [PMID: 22671931]
[53]
Lembo, A.J.; Lacy, B.E.; Zuckerman, M.J.; Schey, R.; Dove, L.S.; Andrae, D.A.; Davenport, J.M.; McIntyre, G.; Lopez, R.; Turner, L.; Covington, P.S. Eluxadoline for irritable bowel syndrome with diarrhea. N. Engl. J. Med., 2016, 374(3), 242-253.
[http://dx.doi.org/10.1056/NEJMoa1505180] [PMID: 26789872]
[54]
Slattery, S.A.; Niaz, O.; Aziz, Q.; Ford, A.C.; Farmer, A.D. Systematic review with meta-analysis: The prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment. Pharmacol. Ther., 2015, 42(1), 3-11.
[http://dx.doi.org/10.1111/apt.13227] [PMID: 25913530]
[55]
Wedlake, L.; A’Hern, R.; Russell, D.; Thomas, K.; Walters, J.R.; Andreyev, H.J. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther., 2009, 30(7), 707-717.
[http://dx.doi.org/10.1111/j.1365-2036.2009.04081.x] [PMID: 19570102]
[56]
Lacy, B.E.; Mearin, F.; Chang, L.; Chey, W.D.; Lembo, A.J.; Simren, M.; Spiller, R. Bowel disorders. Gastroenterology, 2016, 150(6), 1393-1407.e1395.
[http://dx.doi.org/10.1053/j.gastro.2016.02.031]
[57]
Mottacki, N.; Simrén, M.; Bajor, A. Review article: Bile acid diarrhoea-pathogenesis, diagnosis and management. Aliment. Pharmacol. Ther., 2016, 43(8), 884-898.
[http://dx.doi.org/10.1111/apt.13570] [PMID: 26913381]
[58]
Berger, M.; Gray, J.A.; Roth, B.L. The expanded biology of serotonin. Annu. Rev. Med., 2009, 60(1), 355-366.
[http://dx.doi.org/10.1146/annurev.med.60.042307.110802] [PMID: 19630576]
[59]
Gershon, M.D.; Wade, P.R.; Kirchgessner, A.L.; Tamir, H. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology, 2017, 3, 385-395.
[60]
Atkinson, W.; Lockhart, S.; Whorwell, P.J.; Keevil, B.; Houghton, L.A. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology, 2006, 130(1), 34-43.
[http://dx.doi.org/10.1053/j.gastro.2005.09.031] [PMID: 16401466]
[61]
Viramontes, B.E.; Camilleri, M.; McKinzie, S.; Pardi, D.S.; Burton, D.; Thomforde, G.M. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol., 2001, 96(9), 2671-2676.
[http://dx.doi.org/10.1111/j.1572-0241.2001.04138.x] [PMID: 11569693]
[62]
Hicks, G.A.; Coldwell, J.R.; Schindler, M.; Ward, P.A.; Jenkins, D.; Lynn, P.A.; Humphrey, P.P.; Blackshaw, L.A. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J. Physiol., 2002, 544(3), 861-869.
[http://dx.doi.org/10.1113/jphysiol.2002.025452] [PMID: 12411529]
[63]
Pimentel, M.; Lembo, A.; Chey, W.D.; Zakko, S.; Ringel, Y.; Yu, J.; Mareya, S.M.; Shaw, A.L.; Bortey, E.; Forbes, W.P. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med., 2011, 364(1), 22-32.
[http://dx.doi.org/10.1056/NEJMoa1004409] [PMID: 21208106]
[64]
Wouters, M.M.; Vicario, M.; Santos, J. The role of mast cells in functional GI disorders. Gut, 2016, 65(1), 155-168.
[http://dx.doi.org/10.1136/gutjnl-2015-309151] [PMID: 26194403]
[65]
Wouters, M.M.; Balemans, D.; Van Wanrooy, S.; Dooley, J.; Cibert-Goton, V.; Alpizar, Y.A.; Valdez-Morales, E.E.; Nasser, Y.; Van Veldhoven, P.P.; Vanbrabant, W.; Van der Merwe, S.; Mols, R.; Ghesquière, B.; Cirillo, C.; Kortekaas, I.; Carmeliet, P.; Peetermans, W.E.; Vermeire, S.; Rutgeerts, P.; Augustijns, P.; Hellings, P.W.; Belmans, A.; Vanner, S.; Bulmer, D.C.; Talavera, K.; Vanden Berghe, P.; Liston, A.; Boeckxstaens, G.E. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology, 2016, 150(4), 875-87.e9.
[http://dx.doi.org/10.1053/j.gastro.2015.12.034] [PMID: 26752109]
[66]
Hussain, Z.; Quigley, E.M. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment. Pharmacol. Ther., 2006, 23(4), 465-471.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02776.x] [PMID: 16441466]
[67]
Smart, H.L.; Mayberry, J.F.; Atkinson, M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut, 1986, 27(7), 826-828.
[http://dx.doi.org/10.1136/gut.27.7.826] [PMID: 3755416]
[68]
Koloski, N.A.; Talley, N.J.; Huskic, S.S.; Boyce, P.M. Predictor of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment. Pharmacol. Ther., 2003, 17, 841-851.
[69]
van Tilburg, M.A.L.; Palsson, O.S.; Levy, R.L.; Feld, A.D.; Turner, M.J.; Drossman, D.A.; Whitehead, W.E. Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. BMC Complement. Altern. Med., 2008, 8(1), 46-52.
[http://dx.doi.org/10.1186/1472-6882-8-46] [PMID: 18652682]
[70]
Yang, Z.C.; Yang, S.H.; Yang, S.S.; Chen, D.S. A hospital-based study on the use of alternative medicine in patients with chronic liver and gastrointestinal diseases. Am. J. Chin. Med., 2002, 30(4), 637-643.
[http://dx.doi.org/10.1142/S0192415X02000569] [PMID: 12568291]
[71]
Guo, R.; Canter, P.H.; Ernst, E. A systematic review of randomised clinical trials of individualised herbal medicine in any indication. Postgrad. Med. J., 2007, 83(984), 633-637.
[http://dx.doi.org/10.1136/pgmj.2007.060202] [PMID: 17916871]
[72]
Ak, T.; Gülçin, I. Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact., 2008, 174(1), 27-37.
[http://dx.doi.org/10.1016/j.cbi.2008.05.003] [PMID: 18547552]
[73]
Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59.
[http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID: 18662800]
[74]
Derosa, G.; Maffioli, P.; Simental-Mendía, L.E.; Bo, S.; Sahebkar, A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res., 2016, 111, 394-404.
[http://dx.doi.org/10.1016/j.phrs.2016.07.004] [PMID: 27392742]
[75]
Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern. Med. Rev., 2009, 14(2), 141-153.
[PMID: 19594223]
[76]
Ng, Q.X.; Soh, A.Y.S.; Loke, W.; Lim, D.Y.; Yeo, W-S. The role of inflammation in Irritable Bowel Syndrome (IBS). J. Inflamm. Res., 2018, 11, 345-349.
[http://dx.doi.org/10.2147/JIR.S174982] [PMID: 30288077]
[77]
Lubbad, A.; Oriowo, M.A.; Khan, I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol. Cell. Biochem., 2009, 322(1-2), 127-135.
[http://dx.doi.org/10.1007/s11010-008-9949-4] [PMID: 19002562]
[78]
Holt, P.R.; Katz, S.; Kirshoff, R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig. Dis. Sci., 2005, 50(11), 2191-2193.
[http://dx.doi.org/10.1007/s10620-005-3032-8] [PMID: 16240238]
[79]
Yu, Y.; Wu, S.; Li, J.; Wang, R.; Xie, X.; Yu, X.; Pan, J.; Xu, Y.; Zheng, L. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: Involvement of 5-HT-dependent signaling. Metab. Brain Dis., 2015, 30(1), 47-55.
[http://dx.doi.org/10.1007/s11011-014-9554-z] [PMID: 24807589]
[80]
Srivastava, K.C.; Mustafa, T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med. Hypotheses, 1992, 39(4), 342-348.
[http://dx.doi.org/10.1016/0306-9877(92)90059-L] [PMID: 1494322]
[81]
Ghayur, M.N.; Gilani, A.H. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig. Dis. Sci., 2005, 50(10), 1889-1897.
[http://dx.doi.org/10.1007/s10620-005-2957-2] [PMID: 16187193]
[82]
Terry, R.; Posadzki, P.; Watson, L.K.; Ernst, E. The use of ginger (Zingiber officinale) for the treatment of pain: A systematic review of clinical trials. Pain Med., 2011, 12(12), 1808-1818.
[http://dx.doi.org/10.1111/j.1526-4637.2011.01261.x] [PMID: 22054010]
[83]
Pittler, M.H.; Ernst, E. Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis. Am. J. Gastroenterol., 1998, 93(7), 1131-1135.
[http://dx.doi.org/10.1111/j.1572-0241.1998.00343.x] [PMID: 9672344]
[84]
Hills, J.M.; Aaronson, P.I. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology, 1991, 101(1), 55-65.
[http://dx.doi.org/10.1016/0016-5085(91)90459-X] [PMID: 1646142]
[85]
Kligler, B.; Chaudhary, S. Peppermint oil. Am. Fam. Physician, 2007, 75(7), 1027-1030.
[PMID: 17427617]
[86]
Zhang, X.J.; Li, Z.; Leung, W.M.; Liu, L.; Xu, H.X.; Bian, Z.X. The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats. J. Pain, 2008, 9(6), 497-505.
[http://dx.doi.org/10.1016/j.jpain.2007.12.009] [PMID: 18387856]
[87]
Rahimi, R.; Nikfar, S.; Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(1), 118-127.
[http://dx.doi.org/10.1016/j.pnpbp.2008.10.018] [PMID: 19028540]
[88]
Wan, H.; Chen, Y. Effects of antidepressive treatment of Saint John’s wort extract related to autonomic nervous function in women with irritable bowel syndrome. Int. J. Psychiatry Med., 2010, 40(1), 45-56.
[http://dx.doi.org/10.2190/PM.40.1.d] [PMID: 20565044]
[89]
Eamlamnam, K.; Patumraj, S.; Visedopas, N.; Thong-Ngam, D. Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. World J. Gastroenterol., 2006, 12(13), 2034-2039.
[http://dx.doi.org/10.3748/wjg.v12.i13.2034] [PMID: 16610053]
[90]
Werawatganon, D.; Rakananurak, N.; Sallapant, S.; Prueksapanich, P.; Somanawat, K.; Klaikeaw, N.; Rerknimitr, R. Aloe vera attenuated gastric injury on indomethacin-induced gastropathy in rats. World J. Gastroenterol., 2014, 20(48), 18330-18337.
[http://dx.doi.org/10.3748/wjg.v20.i48.18330] [PMID: 25561799]
[91]
Shoba, F.G.; Thomas, M. Study of antidiarrhoeal activity of four medicinal plants in castor-oil induced diarrhoea. J. Ethnopharmacol., 2001, 76(1), 73-76.
[http://dx.doi.org/10.1016/S0378-8741(00)00379-2] [PMID: 11378284]
[92]
Dhuley, J.N. Investigation on the gastroprotective and antidiarrhoeal properties of Aegle marmelos unripe fruit extract. Hindustan Antibiot. Bull., 2003, 45-46(1-4), 41-46.
[PMID: 16281828]
[93]
Rahimi, R.; Abdollahi, M. Herbal medicines for the management of irritable bowel syndrome: A comprehensive review. World J. Gastroenterol., 2012, 18(7), 589-600.
[http://dx.doi.org/10.3748/wjg.v18.i7.589] [PMID: 22363129]
[94]
Bahrami, H.R.; Hamedi, S.; Salari, R.; Noras, M. Herbal medicines for the management of irritable bowel syndrome: A systematic review. Electron. Physician, 2016, 8(8), 2719-2725.
[http://dx.doi.org/10.19082/2719] [PMID: 27757180]
[95]
Sigaeva, V.A.; Malinina, E.A.; Gaziev, A.I. Formation of UV-induced DNA-protein cross-links in bacterial cells and the potentials for their elimination. Radiobiologiia, 1981, 21(4), 568-571.
[PMID: 7029608]
[96]
Kim, Y.J.; Ban, D.J. Prevalence of irritable bowel syndrome, influence of lifestyle factors and bowel habits in Korean college students. Int. J. Nurs. Stud., 2005, 42(3), 247-254.
[http://dx.doi.org/10.1016/j.ijnurstu.2004.06.015] [PMID: 15708012]
[97]
Lustyk, M.K.; Jarrett, M.E.; Bennett, J.C.; Heitkemper, M.M. Does a physically active lifestyle improve symptoms in women with irritable bowel syndrome? Gastroenterol. Nurs., 2001, 24(3), 129-137.
[http://dx.doi.org/10.1097/00001610-200105000-00007] [PMID: 11847862]
[98]
Kuttner, L.; Chambers, C.T.; Hardial, J.; Israel, D.M.; Jacobson, K.; Evans, K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res. Manag., 2006, 11(4), 217-223.
[http://dx.doi.org/10.1155/2006/731628] [PMID: 17149454]
[99]
Takahashi, T. Acupuncture for functional gastrointestinal disorders. J. Gastroenterol., 2006, 41(5), 408-417.
[http://dx.doi.org/10.1007/s00535-006-1773-6] [PMID: 16799881]
[100]
Sung, J.J.Y. Acupuncture for gastrointestinal disorders: Myth or magic. Gut, 2002, 51(5), 617-619.
[http://dx.doi.org/10.1136/gut.51.5.617] [PMID: 12377792]
[101]
Ouyang, H.; Chen, J.D.Z. Review article: Therapeutic roles of acupuncture in functional gastrointestinal disorders. Aliment. Pharmacol. Ther., 2004, 20(8), 831-841.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02196.x] [PMID: 15479354]
[102]
Chan, J.; Carr, I.; Mayberry, J.F. The role of acupuncture in the treatment of irritable bowel syndrome: A pilot study. Hepatogastroenterology, 1997, 44(17), 1328-1330.
[PMID: 9356848]
[103]
Tovey, P. A single-blind trial of reflexology for irritable bowel syndrome. Br. J. Gen. Pract., 2002, 52(474), 19-23.
[PMID: 11791811]
[104]
Madkour, A.A.; Madina, E.M.; el-Azzouni, O.E.; Amer, M.A.; el-Walili, T.M.; Abbass, T. Smectite in acute diarrhea in children: A double-blind placebo-controlled clinical trial. J. Pediatr. Gastroenterol. Nutr., 1993, 17(2), 176-181.
[http://dx.doi.org/10.1097/00005176-199308000-00008] [PMID: 8229544]
[105]
Szajewska, H.; Dziechciarz, P.; Mrukowicz, J. Meta-analysis: Smectite in the treatment of acute infectious diarrhoea in children. Aliment. Pharmacol. Ther., 2006, 23(2), 217-227.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02760.x] [PMID: 16393300]
[106]
Yao-Zong, Y.; Shi-Rong, L.; Delvaux, M. Comparative efficacy of dioctahedral smectite (Smecta) and a probiotic preparation in chronic functional diarrhoea. Dig. Liver Dis., 2004, 36(12), 824-828.
[http://dx.doi.org/10.1016/j.dld.2004.07.012] [PMID: 15646430]
[107]
Chang, F.Y.; Lu, C.L.; Chen, C.Y.; Luo, J.C. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J. Gastroenterol. Hepatol., 2007, 22(12), 2266-2272.
[http://dx.doi.org/10.1111/j.1440-1746.2007.04895.x] [PMID: 17559369]
[108]
Harris, L.R.; Roberts, L. Treatments for irritable bowel syndrome: Patients’ attitudes and acceptability. BMC Complement. Altern. Med., 2008, 8(1), 65.
[http://dx.doi.org/10.1186/1472-6882-8-65] [PMID: 19099570]
[109]
Heizer, W.D.; Southern, S.; McGovern, S. The role of diet in symptoms of irritable bowel syndrome in adults: A narrative review. J. Am. Diet. Assoc., 2009, 109(7), 1204-1214.
[http://dx.doi.org/10.1016/j.jada.2009.04.012] [PMID: 19559137]
[110]
Lea, R.; Whorwell, P.J. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am., 2005, 34(2), 247-255.
[http://dx.doi.org/10.1016/j.gtc.2005.02.005] [PMID: 15862933]
[111]
Daley, A.J.; Grimmett, C.; Roberts, L.; Wilson, S.; Fatek, M.; Roalfe, A.; Singh, S. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: A randomised controlled trial. Int. J. Sports Med., 2008, 29(9), 778-782.
[http://dx.doi.org/10.1055/s-2008-1038600] [PMID: 18461499]
[112]
Levy, R.L.; Linde, J.A.; Feld, K.A.; Crowell, M.D.; Jeffery, R.W. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin. Gastroenterol. Hepatol., 2005, 3(10), 992-996.
[http://dx.doi.org/10.1016/S1542-3565(05)00696-8] [PMID: 16234045]
[113]
Villoria, A.; Serra, J.; Azpiroz, F.; Malagelada, J.R. Physical activity and intestinal gas clearance in patients with bloating. Am. J. Gastroenterol., 2006, 101(11), 2552-2557.
[http://dx.doi.org/10.1111/j.1572-0241.2006.00873.x] [PMID: 17029608]
[114]
Ong, D.K.; Mitchell, S.B.; Barrett, J.S.; Shepherd, S.J.; Irving, P.M.; Biesiekierski, J.R.; Smith, S.; Gibson, P.R.; Muir, J.G. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J. Gastroenterol. Hepatol., 2010, 25(8), 1366-1373.
[http://dx.doi.org/10.1111/j.1440-1746.2010.06370.x] [PMID: 20659225]
[115]
Saberi-Firoozi, M.; Khademolhosseini, F.; Mehrabani, D.; Yousefi, M.; Salehi, M.; Heidary, S.T. Subjective lactose intolerance in apparently healthy adults in southern Iran: Is it related to irritable bowel syndrome? Indian J. Med. Sci., 2007, 61(11), 591-597.
[http://dx.doi.org/10.4103/0019-5359.37045] [PMID: 18025745]
[116]
Gupta, D.; Ghoshal, U.C.; Misra, A.; Misra, A.; Choudhuri, G.; Singh, K. Lactose intolerance in patients with irritable bowel syndrome from northern India: A case-control study. J. Gastroenterol. Hepatol., 2007, 22(12), 2261-2265.
[http://dx.doi.org/10.1111/j.1440-1746.2007.04986.x] [PMID: 17559357]
[117]
Saha, L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J. Gastroenterol., 2014, 20(22), 6759-6773.
[http://dx.doi.org/10.3748/wjg.v20.i22.6759] [PMID: 24944467]
[118]
Hawkey, C.J. Irritable bowel syndrome clinical trial design: Future needs. Am. J. Med., 1999, 107(5A), 98S-102S.
[http://dx.doi.org/10.1016/S0002-9343(99)00087-X] [PMID: 10588180]
[119]
Pimentel, M.; Talley, N.J.; Quigley, E.M.; Hani, A.; Sharara, A.; Mahachai, V. Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology, 2013, 144(7), e1-e5.
[http://dx.doi.org/10.1053/j.gastro.2013.04.049] [PMID: 23644078]
[120]
Trentacosti, A.M.; He, R.; Burke, L.B.; Griebel, D.; Kennedy, D.L. Evolution of clinical trials for irritable bowel syndrome: Issues in end points and study design. Am. J. Gastroenterol., 2010, 105(4), 731-735.
[http://dx.doi.org/10.1038/ajg.2010.12] [PMID: 20372121]
[121]
Quartero, A.O.; Meineche-Schmidt, V.; Muris, J.; Rubin, G.; de Wit, N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev., 2005, 2(2), CD003460.
[PMID: 15846668]
[122]
Kasich, A.M. Treatment of diarrhea in irritable colon, including preliminary observations with a new antidiarrheal agent, diphenoxylate hydrochloride (Lomotil). Am. J. Gastroenterol., 1961, 35, 46-49.
[PMID: 13751669]
[123]
Lavö, B.; Stenstam, M.; Nielsen, A.L. Loperamide in treatment of irritable bowel syndrome-a double-blind placebo controlled study. Scand. J. Gastroenterol. Suppl., 1987, 130(sup130), 77-80.
[http://dx.doi.org/10.3109/00365528709091003] [PMID: 3306903]
[124]
Hovdenak, N. Loperamide treatment of the irritable bowel syndrome. Scand. J. Gastroenterol. Suppl., 1987, 130(sup130), 81-84.
[http://dx.doi.org/10.3109/00365528709091004] [PMID: 3306904]
[125]
Andresen, V.; Montori, V.M.; Keller, J.; West, C.P.; Layer, P.; Camilleri, M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin. Gastroenterol. Hepatol., 2008, 6(5), 545-555.
[http://dx.doi.org/10.1016/j.cgh.2007.12.015] [PMID: 18242143]
[126]
Ford, A.C.; Brandt, L.J.; Young, C.; Chey, W.D.; Foxx-Orenstein, A.E.; Moayyedi, P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am. J. Gastroenterol., 2009, 104(7), 1831-1843.
[http://dx.doi.org/10.1038/ajg.2009.223] [PMID: 19471254]
[127]
Fukudo, S.; Kinoshita, Y.; Okumura, T.; Ida, M.; Akiho, H.; Nakashima, Y.; Nishida, A.; Haruma, K. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology, 2016, 150(2), 358-66.e8.
[http://dx.doi.org/10.1053/j.gastro.2015.10.047] [PMID: 26551550]
[128]
Matsueda, K.; Harasawa, S.; Hongo, M.; Hiwatashi, N.; Sasaki, D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand. J. Gastroenterol., 2008, 43(10), 1202-1211.
[http://dx.doi.org/10.1080/00365520802240255] [PMID: 18618371]
[129]
Garsed, K.; Chernova, J.; Hastings, M.; Lam, C.; Marciani, L.; Singh, G.; Henry, A.; Hall, I.; Whorwell, P.; Spiller, R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut, 2014, 63(10), 1617-1625.
[http://dx.doi.org/10.1136/gutjnl-2013-305989] [PMID: 24334242]
[130]
Basseri, R.J.; Weitsman, S.; Barlow, G.M.; Pimentel, M. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol. Hepatol. (N. Y.), 2011, 7(7), 455-493.
[PMID: 22298980]
[131]
Vork, L.; Mujagic, Z.; Drukker, M.; Keszthelyi, D.; Conchillo, J.M.; Hesselink, M.A.M.; van Os, J.; Masclee, A.A.M.; Leue, C.; Kruimel, J.W. The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. Neurogastroenterol. Motil., 2019, 31(1), e13515.
[http://dx.doi.org/10.1111/nmo.13515] [PMID: 30460734]
[132]
Rahimi, R.; Nikfar, S.; Rezaie, A.; Abdollahi, M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: A meta-analysis. World J. Gastroenterol., 2009, 15(13), 1548-1553.
[http://dx.doi.org/10.3748/wjg.15.1548] [PMID: 19340896]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy